Overview

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Status:
Completed

Trial end date:
2010-03-19

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Sitagliptin Phosphate